International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 5 Sep - Oct 2024, pp: 836-839 www.ijprajournal.com ISSN: 2456-4494

# The Significance of Real-World Evidence in Pharmacovigilance: Enhancing the Drug Safety Monitoring

**Author:** Pandey Aditya Raysahab , **Co-Author:** 1) Devansh Dubey, 2) Sushant marchande, 3) Vishvajit Subhash Gaikwad. **Guided by:** Nayana Sharad Gadhave.

Date of Submission: 05-10-2024 Date of Acceptance: 15-10-2024

**ABSTRACT:** Pharmacovigilance is focused on examining the safety of pharmaceuticals after they are marketed. Traditionally, it relies on data from clinical trials and mechanisms for impulsive reporting to determine adverse drug reactions (ADRs). Although, the scope of clinical trials is frequently limited, excluding certain population analysis and realistic conditions of the world [1]. Regardless of these disadvantages, Real World Evidence (RWE) enhances a useful tool that uses data from sources like patient registries, insurance claims, and electronic health records (EHRs) to recognize adverse drug reactions (ADRs) and contribute to enhanced comprehension of medication safety in variant populations. Firstly, Pharmacovigilance is the science of identifying, evaluating, and averting drug side effects, and is crucial to assure the reliability of pharmaceutical products after they are distributed in the market [2].

## I. INTRODUCTION:

Pharmacovigilance has traditionally been based on clinical trials and impulsive reporting systems to determine and analyze adverse drug reactions (ADRs). Clinical trials have traditionally been the main sources of drug safety information. However premarket trial limitations like small sample sizes, restricted settings, and the precluding of specific populations have provided Real World Evidence (RWE) in pharmacovigilance. Real World Evidence (RWE) however has been an essential tool in pharmacovigilance over recent years, providing insights into medication safety that are usually used in clinical studies [1].

Currently, Real-World Evidence (RWE) has arisen as a crucial tool in pharmacovigilance, contributing awareness into drug safety that traditional clinical trials cannot provide. RWE is derived from Real-World Data (RWD) sources such as electronic health records (EHRs), insurance claims, patient registries, and patient reported outcomes, to confine a wide and diverse patient population. Consider all inclusive evaluation of drug safety, capturing ADRs across different population analysis,multiple chronic condition conditions and varied healthcare settings [2].

### 1. Real-World Evidence in Pharmacovigilance and its significance:

RWE refers to survey of data from actual patient's experiences in routine clinical settings, providing awareness that cannot be obtained from randomized clinical trials (RCTs). Unlike RCTs, which involve expansion and exclusion criteria, RWE captures information from wide populations, including patients with coexisting, pregnant women, and the elderly, who are often excluded from clinical trials [1].This makes RWE critical for understanding the long term safety of drugs once they are approved for general population.

Pharmacovigilance systems like the FDA sentinel initiative and the European Medicines Agencies (EMA) EudraVigilance now incorporate RWE to detect rare or delayed ADRs that might not have been evident in clinical trials. For instance, post market safety monitoring for drugs like rofecoxib and thalidomide revealed severe ADRs that were not identified during clinical development [2].

2. **Sources of Real World Data (RWD):** RWD works on the foundation of RWE offering wide datasets from multiple sources. Common RWD sourses include:

- **Electronic Health Records (EHRs) :** It contributes broad patient information including diagnosis, medication, and treatment outcomes. Systems like FDAs Sentinel Initiative analyze EHRs to examine ADRs in real-time. It contributes to about 40% in overall sources of RWE .
- **Insurance claims:** Claims data provide information about medication usage. Healthcare cost and hospitalization, offering

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 5 Sep - Oct 2024, pp: 836-839 www.ijprajournal.com ISSN: 2456-4494

valuable insights into drug safety across large patient informationIt contributes to about 30% in overall sources of RWE.

- **Patients Registries:** These databases track specific treatment or condition overtime and are critical to understand drug effects on certain subpopulations [4].It contributes to about 19% in overall sources of RWE.
- **Social media and patient forums:** AI-powered tools are now analyzing social media and online patient communities to detect patient reported ADRs earlier than traditional sources.It contributes to about 8% in overall sources of RWE.




3. **Impact of RWE on signals detection:** Signal detection is the process of identifying potential ADRs is significantly enhanced by using different technology in RWE. By analyzing wide ranges of real world datasets, AI and machine learning algorithms can identify ADRs that might not be seen in smaller clinical trial datasets. Different studies have shown that using RWE can improve the early detection of ADRs, leading to more safety interventions [6].

For example, EHRs based systems like the UK yellow card scheme integrated with RWE sources, have successfully detected signals for drugs like the anticoagulant warfarin and vaccines, contributing to promoting regulatory action.

4. **RWE and Regulatory Decision Making:** In India, the regulatory framework for pharmacovigilance is primarily governed by the Central Drug Standard Control Organization (CDSCO). The CDSCO, under the ministry of Health and family Welfare, plays a vital role in overseeing drug safety and ensuring regulatory compliance. The Drug Controller General of India (DCGI) supervises the implementation of pharmacovigilance regulations. Collaboratively, these agencies issue guidelines and regulations, ensuring that pharmaceutical companies adhere to stringent reporting and safety monitoring requirements [11].

Regulatory agencies such as the U.S. FDA, and EMA, are increasingly incorporating RWE into their decision making processess. The 21st century Cures Act (2001) and the FDAs RWE Framework (2018) outline how RWE can be used to support post market surveillance, label updates, and even new drug approvals.The EMA has also launched initiatives, such as the adaptive pathway program, which uses RWE to expedite the approval process for high need medicines while maintaining safety standards.

5. **Case studies of RWE in Pharmacovigilance:** Several case studies demonstrate the effectiveness of RWE in pharmacovigilance:

- **COVID-19 Vaccines:** The rapid development and rollout COVID-19 vaccines highlighted the importance of RWE in drug safety monitoring. Global pharmacovigilance systems have relied heavily on RWE to monitor the safety and effectiveness of vaccines across diverse populations, detecting rare ADRs like myocarditis and thrombosis following mRNA vaccination [8].
- **Diabetes Medications:** Post market surveillance of sodium-glucose cotransporter-2 (SGLT2) inhibitors for diabetes, using insurance claims and EHR data, revealed a higher- than-expected risk of ketoacidosis, leading to updated safety warnings by regulatory agencies [10].

6. **Challenges in using RWE for pharmacovigilance:**

fig. Challenges in RWE

- **Data Quality and Completeness:** Real-world data frequently lack the standardization and precision of clinical trial data. Incompatible with medical records, incomplete insurance

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 5 Sep - Oct 2024, pp: 836-839 www.ijprajournal.com ISSN: 2456-4494

claims, and patient registries missing crucial details such as dosage or outcomes can introduce biases. This decreases the dependability of RWE in detecting rare or delayed adverse drug reactions (ADRs). Efforts are ongoing to standardize data collection and enhance quality mechanisms [11].

- **Data integration and interoperability:** RWE typically pulls data from diverse sources like EHRs, claims, and patient reported outcomes, which may not be compatible. Variation in data formats across healthcare systems globally hinder the integration of international RWD, limiting the global reach of pharmacovigilance efforts. Initiatives like FDA's Sentinel system have improved integration, but global standardization remains a challenge [2].
- **Regular and Ethical challenges:** The use of RWE raises ethical concerns about data privacy and patient consent, particularly given the large scale of sensitive patient information. Compliance with data protection laws such as GDPR (General data protection regulation) and HIPAA ( health insurance portability and accountability act) is essential. Furthermore, while RWE is gaining recognition from regulators, its validation for formal decision making is still envolving, with agencies like the FDA and EMA requiring strict evidence standards [4].
- **Analytical Complexity:** Analyzing RWE is far more complex than analyzing clinical trial data. Real world datasets are large, diverse, and noisy, requiring sophisticated statistical and machine learning tools to detect valid safety singals. Confounding factors, such as comorbidities and concurrent medications, make it challenging to establish causality between drugs and adverse events [2].
- **Timeless data:** RWD is often collected retrospectively, which may result in delays.The absence of real time data capture in many healthcare systems hampers the timely detection of safety signals, potentially delaying necessary intervention and increasing risks to public health.

By addressing these challenges, RWE can significantly improve pharmacovigilance efforts, especially through advancements in technology, standardization, and analytical methods.



Fig. challenges in using RWE in Pharmacovigilance

7. **Future scope:** The future of pharmacovigilance lies in expanded use of real world evidence

(RWE), powered by advances in artificial intelligence (AI) and machine learning. AI tools are already being utilized to analyze large, real world datasets, improving signal detection and risk prediction[13]. As data intregration technologies advance, pharmacovigilance systems will be able to process even large datasets in real time, making drug safety monitoring more proactive and comprehensive. It also helps to enhance the life science researches, clinical trials and their studies, in post marketing surveillance and different fields [5].

## II. CONCLUSION:

Real-World Evidence (RWE) is transforming pharmacovigilance by providing insights into drug safety that cannot be obtained from clinical trials alone. With its ability to gather data from diverse patient populations and real world healthcare settings, RWE is becoming an indispensable tool in ensuring drug safety in the post market. As technology continues to advance, integrating RWE into pharmacovigilance systems will enhance the early detection of adverse drug reactions (ADRs), reduce harm, and promote the safe and effective use of medicines globally [15,16].

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 5 Sep - Oct 2024, pp: 836-839 www.ijprajournal.com ISSN: 2456-4494

## REFERENCE:

[1]. The role of RWE in drug safety monitoring, Journal of clinical Pharmacology, 2020, page no. 78-85.
[2]. Post marketing surveillance using real world data ,Drug Safety journal,2019 , vol 42, page no. 543-552
[3]. Platt, R. et al. The FDA Sentinel Initiatives-an evolving national resources. N. Engl. J. Med. 379, 2091-2093 ( 2018). Google scholar
[4]. Patients registries in Pharmacovigilance, Journal of Pharmaceutical sciences, 2021, vol 114 ,page no 252- 258.
[5]. AI and social media Analytics in pharmacovigilance, Journal of Medical Internet Research, 2020,vol.22 page no. e12191.
[6]. Enhancing signal detection with Real-World Evidence, Frontiers in pharmacology, 2019, Vol. 10, Article 1015 .
[7]. Schneeweiss, S., & Patorno, E. (2021.) conducting real world evidence studies on the clinical outcomes of diabetes treatments. view
[8]. Monitoring COVID 19 vaccines safety Using real world evidence, New England Journal of Medicines, 2021 page no. 1234-1240.
[9]. Post market Surveillance of covid 19 vaccines, Vaccines Safety Journal, 2021, page no. 45-52.
[10]. SGLT2 Inhibitors and the Role of RWE in Pharmacovigilance, Diabetes care, 2020, Vol. 43 page no. 850-857.
[11]. Aronson, J.K. ( 2011a) Adverse drug reaction: history, terminology, classification, causality, frequency,preventability. In: J. Talbot & J.K. Arosons (eds), Stephens Detection and Evaluation of Adverse Drug Reactions: Principles and Practice,Th edn, pp. 1-119.
[12]. Willey-Blackwell,Oxford.GoogleScholar Data Privacy Concerns in Real World Evidence Studies, Journal of Pharmacovigilance, 2020, vol.47 page no. 75-82 .
[13]. The Future of Real-Word Evidence in Pharmacovigilance, International Journal of Drug Safety, 2021 page no. 230-239.
[14]. Wearable and Mobile Health Application in Pharmacovigilance, Journal of Digital Health, 2020, page no 185-190.
[15]. Integration of RWD in Regulatory Decision MAking, Journal of Regulatory Science, 2020, page no. 91-100.
[16]. Sahoo, A.K. and Varshney, (2018). Artificial Intelligence in Drug Safety Surveillance. Emerging technology in pharmacovigilance, page no. 121-134.